Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Clinical trial NCT05130177 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05130177
- Sponsor
- Diwakar Davar
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-16
- Primary completion
- 2026-02-06
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.